Content
Tricida Could Topple With Lock-Up Expiration
Article By:
Don Dion
Read
Monday, December 24, 2018 12:10 AM EDT
When TCDA's IPO lock-up expires on December 25, pre-IPO shareholders and company insiders will be able to cash in on gains and sell currently-restricted shares. Risk-tolerant investors should consider shorting shares ahead of the lock-up expiration.
In this article: TCDA
Week In Review: Two China Biopharmas Raise $1.4 Billion In Hong Kong IPOs
Article By:
ChinaBio® Today
Read
Saturday, December 15, 2018 4:06 PM EDT
WuXi AppTec began trading on the Hong Kong Exchange following a $967 million IPO, finishing the first day of trading at the offer price. In May, the company completed a $354 million Shanghai IPO at a price that has now quadrupled after six months.
In this article: ZLAB
Legacy Housing Corporation Is A Good Old Fashioned Business
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Article By:
ChinaBio® Today
Read
Saturday, December 8, 2018 4:21 PM EDT
WuXi AppTec, China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range (see story). In May, WuXi became a public company by completing a $328 million IPO in Shanghai.
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By:
ChinaBio® Today
Read
Saturday, December 1, 2018 4:44 PM EDT
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
Week In Review: CStone Pharma, A Suzhou Oncology Company, Files For Hong Kong IPO
Article By:
ChinaBio® Today
Read
Saturday, November 17, 2018 5:26 PM EDT
Suzhou's CStone Pharma has filed for a Hong Kong IPO. Founded in 2015, CStone has quickly built a portfolio of 14 oncology candidates.
Week In Review: BioMérieux Acquires Majority Stake In China Diagnostics Company For $114 Million
Article By:
ChinaBio® Today
Read
Saturday, November 10, 2018 4:08 PM EDT
French in vitro diagnostics company, bioMérieux (Paris: BIM), acquired a majority stake in Suzhou Hybiome Biomedical Engineering for $114 million. Hybiome specializes in automated immunoassay tests.
RUBY - A Biotech Based On A Flawed Premise
Article By:
Will Brody
Read
Thursday, November 8, 2018 2:10 PM EDT
Rubius is a recent IPO. On closer examination, I believe that the company is based entirely on a flawed scientific concept.
In this article: RUBY
Pluralsight Could Falter When Lockup Expires
Week In Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week
Article By:
ChinaBio® Today
Read
Saturday, October 27, 2018 5:08 PM EDT
Innovent Biologics has priced its Hong Kong IPO to raise $421 million. The successful IPO shows investors are still interested in young China biopharmas. he IPO values Innovent at $2 billion; its shares will begin trading on October 31.
Funding Secured
Article By:
Ben Hunt
Read
Sunday, October 21, 2018 1:35 PM EDT
Can you imagine if Tesla were moving forward with the Saudi sovereign wealth fund in a take-private transaction? Can you imagine the uproar over doing this sort of major deal with the Saudis after the Khashoggi murder? Well, no need to imagine.
In this article: WE
Week In Review: Innovent's Hong Kong IPO: Raising $422 Million At $2 Billion Valuation
Article By:
ChinaBio® Today
Read
Saturday, October 20, 2018 4:16 PM EDT
Innovent Biologics of Suzhou plans to raise $422 million in its Hong Kong IPO at a $2 billion valuation, according to multiple media reports. The company, formed in 2011, struck a major $1 billion collaboration with Lilly in 2015.